Spyro Mousses PhD
Founder and CEO
Oligon RNA Therapeutics
SPYRO MOUSSES, PHD
FOUNDER AND CEO, OLIGON RNA THERAPEUTICS
BIOSKETCH: Dr. Mousses received his PhD from the University of Toronto, Canada. Following that he completed a Fellowship, followed by a Staff Scientist position at the National Human Genome Research Institute, NIH in Bethesda MD, USA. Then he served as Director of Pharmaceutical Genomics Division at the Translational Genomics Research Institute (TGen), a non-profit research institute. Dr. Mousses has also served as a scientific advisor to the pharmaceutical and industry and collaborated with various technology groups, including Lilly, GSK, BMS, Merck KGaA, Cisco, Dell, CHOC MI4, and AIMed. In 2015, he co-founded Systems Oncology LLC (SO), an early therapeutic and technology incubator which used AI and computational biology to discover and develop innovative therapeutics. One of the biggest scientific breakthroughs to be developed and incubated by Dr. Mousses at Systems Oncology was the SeekR RNA therapeutic platform. The SeekR platform technology was acquired by Mousses Ventures in 2023, and it is being commercialized through partnerships. The most recent is a VC-backed biotechnology company called Oligon RNA Therapeutics, which is leveraging AI-empowered drug discovery to develop a pipeline of next generation SeekR immunotherapy drugs.
FOUNDER AND CEO, OLIGON RNA THERAPEUTICS
BIOSKETCH: Dr. Mousses received his PhD from the University of Toronto, Canada. Following that he completed a Fellowship, followed by a Staff Scientist position at the National Human Genome Research Institute, NIH in Bethesda MD, USA. Then he served as Director of Pharmaceutical Genomics Division at the Translational Genomics Research Institute (TGen), a non-profit research institute. Dr. Mousses has also served as a scientific advisor to the pharmaceutical and industry and collaborated with various technology groups, including Lilly, GSK, BMS, Merck KGaA, Cisco, Dell, CHOC MI4, and AIMed. In 2015, he co-founded Systems Oncology LLC (SO), an early therapeutic and technology incubator which used AI and computational biology to discover and develop innovative therapeutics. One of the biggest scientific breakthroughs to be developed and incubated by Dr. Mousses at Systems Oncology was the SeekR RNA therapeutic platform. The SeekR platform technology was acquired by Mousses Ventures in 2023, and it is being commercialized through partnerships. The most recent is a VC-backed biotechnology company called Oligon RNA Therapeutics, which is leveraging AI-empowered drug discovery to develop a pipeline of next generation SeekR immunotherapy drugs.
